TISSUEGEN
THE PRODUCTION OF A 3D HUMAN TISSUE DISEASE PLATFORM TO ENABLE REGENERATIVE MEDICINE THERAPY DEVELOPMENT
| Coordinatore | Cn Bio Innovations Limited
Organization address
address: 30 UPPER HIGH STREET contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 4˙291˙627 € |
| EC contributo | 3˙071˙055 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2011-two-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-01-01 - 2015-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
Cn Bio Innovations Limited
Organization address
address: 30 UPPER HIGH STREET contact info |
UK (THAME) | coordinator | 451˙500.00 |
| 2 |
TAKARA BIO EUROPE AB
Organization address
address: ARVID WALLGRENS BACKE 20 contact info |
SE (GOETEBORG) | participant | 1˙216˙325.00 |
| 3 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 630˙280.00 |
| 4 |
MICRONIT MICROFLUIDICS BV
Organization address
address: COLOSSEUM 15 contact info |
NL (ENSCHEDE) | participant | 468˙600.00 |
| 5 |
TRANSTISSUE TECHNOLOGIES GMBH
Organization address
address: CHARITEPLATZ 1 / VIRCHOWWEG 11 contact info |
DE (BERLIN) | participant | 304˙350.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'This project will focus on the production of an in vitro human disease tissue platform technology to enable and accelerate the development of regenerative medicine therapies for a diverse range of diseases. The concept will be realised by the in vitro generation of 3D human tissues cultured from human induced Pluripotent Stem (iPS) cells. Initially a library of adult cells will be generated from patients with a range of genetic diseases. These cells will subsequently be used to generate iPS cell cultures in optimised conditions, with the resultant cells being differentiated into key cell types. These differentiated cells will then be integrated onto 3D tissue bioreactors operating in an optimised variable perfusion environment producing the 3D human tissue disease cultures. The bioreactors will be constructed using a range of innovative microfluidic techniques to produce systems compatible with analysis systems commonly used in laboratories worldwide. The development of a platform technology producing 3D human tissue disease cultures will enable the generation of fully differentiated cell types and thus allow diseases to be effectively modelled at a population relevant scale in 3D human tissues in vitro. The resultant major benefit of the system is that it will allow regenerative therapies to be developed and tested on batteries of human tissues in the laboratory in a rapid, cost effective manner relevant to the in vivo state. To develop and validate the platform technology within the lifetime of the project liver hepatocyte cells and tissues will be generated due to their scientific and commercial significance from a population relevant range of patients with inherited metabolic disorders (IMDs). Therefore this project will significantly advance the state of the art and constitute a significant step forward for the regenerative medicine industry producing a key platform resource.'
Introduzione (Teaser)
Induced pluripotent stem cells (IPSCs) research could allow the growth of a limitless supply of the patient's own cell types to regenerate tissues and organs. This avoids the ethical concerns associated with using stem cells from embryos (ES cells).
Descrizione progetto (Article)
The mission of the EU-funded http://www.tissuegen.org (TISSUEGEN) project is the production of an in vitro human disease tissue platform technology to enable the development of regenerative medicine therapies.
The concept is based on the in vitro generation of 3D human tissues cultured from human IPSCs.
Liver hepatocytes and tissues have been designated for the validation phase due to their scientific and commercial significance.During the first stage of the four-year project partners produced an IPSC library from an inherited metabolic liver disorder donor set and developed key parameters of human pluripotent stem cell culture.
These cells and human hepatocytes have been loaded onto the 3D liver tissue platform.
Work has focused on optimisation of the conditions for the loading of the hepatocytes onto current 3D scaffolds and assessment of hepatocyte functionality over an extended period.Results and achievements of the project have so far been presented in five high-impact publications in peer-reviewed journals.
A successful platform will mean that regenerative therapies can be assessed in a scalable, cost-effective format.3D modelling cancer tissue modelling also promises to increase understanding of these diseases.